Clinical Trial

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned (relapsed) or not responded to treatment (refractory) or have higher risk Myelofibrosis (MF). Participants will receive a study drug infusion on Day 1, Day 4, Day 8 and Day 11 of each 28-day cycle for a total of 6 cycles.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-05
Trial Details
NCT Number NCT07250646
Lead Sponsor Aspera Biomedicines, Inc.
Collaborators: Tempus AI
Conditions Secondary AML, Myelofibrosis
Enrollment 28 participants
Start Date 2026-05-21
Primary Completion 2027-10 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-20